Novo Nordisk not yet ready to bring in popular obesity, diabetes injectables

Novo Nordisk's launch of weight-loss and diabetes drugs Wegovy and Ozempic in India hinges on resolving supply issues. The company is scaling up production and may consider local fill-finish options. Currently, the injectable forms are not approved in India, leading to high demand in grey markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xHSkP0l
via IFTTT